News
-
-
-
COMMUNIQUÉ DE PRESSE
NanoViricides to Present at the BIO International Convention in Boston on Monday, June 16, 2025
NanoViricides to present at BIO International Convention 2025 on June 16 in Boston, MA, showcasing breakthrough antiviral drug NV-387 with broad-spectrum efficacy and unique mechanism -
-
-
COMMUNIQUÉ DE PRESSE
The New Rational FDA COVID Vaccine Policy is Long Overdue, Says NanoViricides' Dr. Diwan
NanoViricides, Inc. comments on the new COVID Vaccine Booster Shots policy adopted by the US FDA with focus on specific high-risk groups. Dr. Anil Diwan emphasizes evidence-based decision making for vaccine boosters -
-
-
COMMUNIQUÉ DE PRESSE
NanoViricides, Inc. Has Filed its Quarterly Report: Broad-Spectrum Antiviral NV-387 To Combat MPox Pandemic in Africa - Phase II Clinical Trial Update, Also Readying to Combat Measles Outbreaks, and to Tackle Bird Flu
NanoViricides, Inc. reports filing Form 10-Q for quarter ending March 31, 2025 with SEC. Clears Phase II trial for NV-387 drug to treat MPox disease & explores Measles and Bird Flu treatments. Company has strong financials -
